Min MIn Qin
Directeur Technique/Scientifique/R&D chez LEPU BIOPHARMA CO., LTD.
Profil
Min MIn Qin currently works at Lepu Biopharma Co., Ltd., as Chief Technology Officer & Senior Vice President from 2020 and Shanghai Miracogen, Inc., as Senior Vice President.
Dr. Qin also formerly worked at BioMarin Pharmaceutical, Inc., as Senior Director-Process Development from 1997 to 2004, Five Prime Therapeutics, Inc., as Senior Director from 2005 to 2012, Wuxi Biologics (Cayman), Inc., as Vice President from 2017 to 2018, HBM Holdings Ltd., as Senior Vice President from 2018 to 2019, Shanghai JMT-BIO Technology Co., Ltd., as Chief Technology Officer from 2012 to 2015, Zhejiang Teruisi Pharmaceutical Co., Ltd., as Chief Technology Officer & Senior Vice President from 2015 to 2016, and Jiangsu Pacific Meinuoke Pharmaceutical Co. Ltd., as Chief Science Officer from 2016 to 2017.
Dr. Qin received his doctorate degree in 1991 from the University of Wisconsin and undergraduate degree in 1981 from Northwest A&F University.
Postes actifs de Min MIn Qin
| Sociétés | Poste | Début |
|---|---|---|
| LEPU BIOPHARMA CO., LTD. | Directeur Technique/Scientifique/R&D | 10/12/2020 |
Shanghai Miracogen, Inc.
 Shanghai Miracogen, Inc. BiotechnologyHealth Technology Part of Lepu Biopharma Co., Ltd., Shanghai Miracogen, Inc. is a Chinese company that engages in the development, clinical research, and industrialization of cancer targeted therapy drugs. The company is based in Pudong, China. The company was founded in 2014 by Chao Hong Hu and Marry Hu. Marry Hu has been the CEO since 2014. | Corporate Officer/Principal | - |
Anciens postes connus de Min MIn Qin
| Sociétés | Poste | Fin |
|---|---|---|
| HBM HOLDINGS LIMITED | Corporate Officer/Principal | 01/04/2019 |
| WUXI BIOLOGICS (CAYMAN) INC. | Corporate Officer/Principal | 01/03/2018 |
| Jiangsu Pacific Meinuoke Pharmaceutical Co. Ltd. | Directeur Technique/Scientifique/R&D | 01/07/2017 |
Zhejiang Teruisi Pharmaceutical Co., Ltd.
 Zhejiang Teruisi Pharmaceutical Co., Ltd. BiotechnologyHealth Technology Zhejiang Teruisi Pharmaceutical Co., Ltd. is a private company based in Zhejiang, China that engages in the production of cancer medicine. | Directeur Technique/Scientifique/R&D | 01/10/2016 |
| Shanghai JMT-BIO Technology Co., Ltd. | Directeur Technique/Scientifique/R&D | 01/09/2015 |
Formation de Min MIn Qin
| Northwest A&F University | Undergraduate Degree |
| University of Wisconsin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| LEPU BIOPHARMA CO., LTD. | Health Technology |
| HBM HOLDINGS LIMITED | Health Technology |
| WUXI BIOLOGICS (CAYMAN) INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Shanghai Miracogen, Inc.
Shanghai Miracogen, Inc. BiotechnologyHealth Technology Part of Lepu Biopharma Co., Ltd., Shanghai Miracogen, Inc. is a Chinese company that engages in the development, clinical research, and industrialization of cancer targeted therapy drugs. The company is based in Pudong, China. The company was founded in 2014 by Chao Hong Hu and Marry Hu. Marry Hu has been the CEO since 2014. | Health Technology |
| Jiangsu Pacific Meinuoke Pharmaceutical Co. Ltd. | |
Zhejiang Teruisi Pharmaceutical Co., Ltd.
Zhejiang Teruisi Pharmaceutical Co., Ltd. BiotechnologyHealth Technology Zhejiang Teruisi Pharmaceutical Co., Ltd. is a private company based in Zhejiang, China that engages in the production of cancer medicine. | Health Technology |
| Shanghai JMT-BIO Technology Co., Ltd. | |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
